Megaw Roly, Dhillon Bal
Scottish Center for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU, UK,
Curr Diab Rep. 2014 Jul;14(7):498. doi: 10.1007/s11892-014-0498-9.
Diabetic retinopathy is the leading cause of blindness in the working population. We now understand that the pathogenesis of the disease contains both a neurodegenerative and vasodegenerative component. Yet despite this, current treatment is still limited to combating the proliferative end stage component of the disease rather than addressing its underlying causes. In recent years, much basic research has focused on demonstrating the potential that several classes of stem cells have in conferring both neuro- and vasoprotection on the diabetic retina. Further, progress has been made in using stem cells to stimulate both neuro and vascular regeneration. This review will discuss the current understanding as to what mechanisms underlie diabetic retinopathy while highlighting the types of stem cells which offer hope as potential novel therapies for diabetic retinopathy, including those that are now in clinical trial.
糖尿病视网膜病变是劳动人口失明的主要原因。我们现在明白,该疾病的发病机制包含神经退行性和血管退行性两个组成部分。然而,尽管如此,目前的治疗仍然局限于对抗该疾病的增殖性终末期成分,而不是解决其根本原因。近年来,许多基础研究集中于证明几类干细胞在为糖尿病视网膜提供神经保护和血管保护方面的潜力。此外,在利用干细胞刺激神经和血管再生方面也取得了进展。本综述将讨论目前对糖尿病视网膜病变潜在机制的理解,同时强调那些有望成为糖尿病视网膜病变潜在新疗法的干细胞类型,包括那些目前正在进行临床试验的干细胞类型。